Written by Pieter Botha
Published in Vol 6 Issue 1, 2026
Programmed death-ligand 1 (PD-L1) and major histocompatibility complex class I (MHC-I) play central roles in enabling tumors to evade immune surveillance and in conferring resistance to PD-1/PD-L1 inhibitors. The present work demonstrates that increased expression of all members of the miR-23a/27a/24−2 cluster is associated with reduced patient survival, heightened immune escape, and diminished responsiveness to PD-1/PD-L1 blockade in individuals with non-small cell lung cancer (NSCLC). Forced e
Written by Santiago Morales
Published in Vol 6 Issue 1, 2026
Long non-coding RNAs (lncRNAs) exert substantial influence on the development and metastatic spread of gastric cancer (GC). Despite this, systematic studies using tissue-derived lncRNAs to predict peritoneal recurrence in GC patients remain insufficient. The current investigation aims to delineate the lncRNA transcriptional profile in GC with peritoneal metastasis (PM) and to develop an integrated lncRNA-derived scoring system to predict peritoneal recurrence in individuals undergoing radical ga
Written by Nora Schneider
Published in Vol 6 Issue 1, 2026
Protein palmitoylation is a reversible lipid modification that plays pivotal roles in various physiological processes. Aberrant palmitoylation frequently contributes to cancer development. However, the precise contributions of S-palmitoylating enzymes, known as palmitoyltransferases, to the initiation and progression of hepatocellular carcinoma (HCC) remain poorly understood. The role of zinc finger DHHC-type palmitoyltransferase 20 (ZDHHC20) in HCC tumorigenesis was assessed using diethylnitros
Written by Daniel Kim
Published in Vol 6 Issue 1, 2026
The majority of patients with colorectal cancer (CRC) show only modest responses to anti-programmed cell death protein 1 (PD-1) treatment, and the precise reasons for this limited efficacy are not yet clear. Circular RNAs (circRNAs) are known to exert substantial influence on tumor formation and progression, offering possible utility in early detection and prediction of therapeutic outcomes. Nevertheless, investigations into the contribution of circRNAs to immune evasion in CRC remain scarce. Di
Written by Mateo Alvarez
Published in Vol 6 Issue 1, 2026
The current analysis evaluated the application of transarterial radioembolization (TARE) in hepatocellular carcinoma (HCC) both for palliation and as a bridge to liver transplantation. In total, 167 patients underwent 245 TARE sessions, comprising 50 patients in the bridging cohort and 117 in the palliative cohort. Fourteen of these individuals later received liver transplantation (LT). Those who advanced to LT showed significantly better progression-free survival (PFS) than patients who receive
Written by Sara Ben Youssef
Published in Vol 6 Issue 1, 2026
The present investigation evaluated the potential added value of preoperative 18F-FDG PET/CT over conventional primary staging procedures in patients diagnosed with presumed non-metastatic colonic cancer (CC). In addition, the study assessed the prognostic implications of 18F-FDG uptake in the primary tumor, with an average follow-up of 15 years. Patients newly diagnosed with apparently localized CC were prospectively recruited and underwent 18F-FDG PET/CT scanning before surgery. SUVmax, SUVpea
Written by Noah Williams
Published in Vol 6 Issue 1, 2026
Pediatric high-grade gliomas (HGGs) arising in the cerebellum remain rare, and detailed accounts in the literature are limited. Medulloblastoma constitutes a major differential diagnosis when encountering poorly differentiated tumors in the pediatric cerebellum. The present study delineates the histological and molecular attributes of five cerebellar high-grade gliomas in children. These neoplasms exhibited considerable histological and immunohistochemical overlap with medulloblastomas and regis
Written by Elena Petrova
Published in Vol 6 Issue 1, 2026
In advanced NSCLC, a specific subgroup of patients exhibits synchronous oligometastatic disease (sOMD), characterized by a low metastatic burden identified at initial diagnosis. Given the established association of cachexia and sarcopenia with reduced survival, these features could help guide decisions on the appropriateness of radical intervention. This retrospective multicenter investigation included all patients with thoroughly staged (via FDG-PET and brain imaging) sOMD fulfilling the EORTC
Written by Lina Hassan
Published in Vol 6 Issue 1, 2026
Cutaneous squamous cell carcinomas (SCCs) emerge as a serious sequela in selected forms of epidermolysis bullosa (EB), carrying elevated risks of morbidity and mortality along with considerable gaps in effective management strategies. Elevated endogenous mutagenesis coupled with a desmoplastic stromal reaction is implicated in disease development. Individuals with dystrophic EB (DEB) and Kindler EB (KEB) are most at risk of SCC formation. A parallel high-risk cohort includes immunosuppressed (IS
Written by Saif Al-Hinai
Published in Vol 6 Issue 1, 2026
To evaluate the preoperative value of ML-driven classification based on conventional 18F-FDG PET metrics and clinical information for forecasting features of EC aggressiveness. A retrospective analysis was conducted on 123 patients with EC who received 18F-FDG PET scans for preoperative staging between 2009 and 2021. SUVmax, SUVmean, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured from the primary lesion. Patient age and body mass index (BMI) were recorded. Histolog
Written by Charlotte Dupuis
Published in Vol 6 Issue 1, 2026
It is well established that [68Ga]Ga-prostate-specific membrane antigen-11 ([68Ga]Ga-PSMA-11) PET/CT offers greater diagnostic precision than [18F]F-Fluorocholine PET/CT for prostate cancer (PCa). Nevertheless, whether this improved accuracy translates into better clinical outcomes in oligometastatic PCa patients managed with [68Ga]Ga-PSMA-11 PET-guided metastasis-directed therapy (MDT) remains unclear. This investigation evaluated the effects of the two imaging modalities on Progression-Free Su
Written by Olivia Bennett
Published in Vol 6 Issue 1, 2026
The pan-immune-inflammation value (PIV), a newly proposed marker, had not yet been assessed in oral cavity squamous cell carcinoma (OSCC). In this investigation, PIV was computed using the formula (neutrophil count × platelet count × monocyte count) / lymphocyte count, derived from automated hematology analyzer results, among 853 OSCC patients treated from 2005 to 2017. The optimal preoperative cutoff for PIV was determined to be 268 via ROC curve analysis. Statistically significant differences
Written by Ethan Wright
Published in Vol 6 Issue 1, 2026
Positive outcomes with HER2-directed ADCs in tumors showing low HER2 expression have challenged the traditional binary (positive/negative) categorization of HER2 status. However, the clinicopathological features and prognostic implications of varying HER2 expression levels in colorectal cancer remain incompletely understood. We conducted a multicenter retrospective analysis of patients with histologically confirmed colorectal cancer who underwent curative resection and had available HER2 status.
Written by Yifan Zhao
Published in Vol 6 Issue 1, 2026
Irregular expression of FBLN5 has been linked to different forms of cancer. The present study represents the initial investigation into its clinical and functional importance in gastric cancer (GC). Using data from The Cancer Genome Atlas-GC (TCGA-GC) and Gene Expression Omnibus (GEO) databases, we identified differences in FBLN5 expression and examined its association with clinicopathological features. Survival analysis via a Kaplan–Meier plotter evaluated FBLN5’s influence on patient prognosis
Written by Erik Van der Meer
Published in Vol 6 Issue 1, 2026
Conventional targeted therapies have shown limited success in extending survival for gastric cancer patients, primarily owing to off-target toxicities and mechanisms of tumor immune evasion. Circular RNAs are abundantly present in tumor tissues, serving as potential biomarkers and promising therapeutic targets. The role of hsa_circ_0136666 in driving gastric cancer cell proliferation was examined using Western blotting, quantitative real-time PCR (qRT-PCR), fluorescence in situ hybridization (FI
Written by Andrei Popescu
Published in Vol 6 Issue 1, 2026
Liver metastasis remains the predominant contributor to mortality in individuals diagnosed with colorectal cancer (CRC). Growing research highlights the significant involvement of circular RNA (circRNA) in driving cancer advancement. Nonetheless, the specific role of circRNA in the development of liver metastasis in CRC remains unclear. Circ-YAP expression levels were assessed by quantitative real-time PCR and in situ hybridization. Functional roles of circ-YAP were investigated using wound-heal
Written by Zsolt Kovács
Published in Vol 6 Issue 1, 2026
Although commercial anti-CD19 chimeric antigen receptor T-cell (CART19) therapies are effective in treating advanced B-cell non-Hodgkin lymphoma (NHL), the majority of patients ultimately relapse. Several factors contribute to treatment failure, such as loss of CD19 expression on tumor cells and functional exhaustion of CAR T cells. All approved CART19 products rely on the FMC63 single-chain variable fragment (scFv), which binds a membrane-distal epitope of CD19 and displays comparatively slow a
Written by Daniel Fischer
Published in Vol 6 Issue 1, 2026
Lysine crotonylation (Kcr) is elevated in colorectal cancer (CRC) tissues, yet its functional significance in disease progression remains unclear. This investigation aimed to determine the specific contribution and molecular pathway of crotonylation at lysine 27 on histone H3 (H3K27cr) in driving CRC metastasis. Immunohistochemical staining was applied to assess the relationship between H3K27cr expression and metastatic features in CRC. Loss-of-function and gain-of-function experiments were carr
Written by Nguyen Thanh Huy
Published in Vol 6 Issue 1, 2026
Individuals diagnosed with mantle cell lymphoma (MCL) demonstrate substantial diversity in both their clinical manifestations and long-term prognosis. Nevertheless, the prognostic tools currently in widespread use are outdated and fail to meet the requirements of modern multidisciplinary care for this malignancy. The current investigation aims to characterize the clinical and pathological features of MCL in the context of immunochemotherapy and to develop enhanced prognostic tools that more reli
Written by Fatima El Idrissi
Published in Vol 6 Issue 1, 2026
T cell engagers (TCEs) have emerged as an important therapeutic approach for hematologic malignancies, yet their effectiveness against solid tumors has been limited. Elevated expression of programmed cell death 1 (PD-1) is closely linked to T cell exhaustion and contributes to immunosuppression driven by the tumor. The creation of a novel nanobody-based trispecific T cell engager (Nb-TriTE) may offer an effective means to enhance treatment outcomes. Leveraging the favorable properties of nanobod
Written by Laura Keller
Published in Vol 6 Issue 1, 2026
Earlier randomized clinical trials demonstrated that regorafenib improves survival in patients with unresectable colorectal cancer, yet it is also linked to a substantial frequency of adverse reactions. To minimize toxicity and enhance patient tolerance, this investigation evaluated body weight–based regorafenib dosing to determine an appropriate regimen. Data were drawn from a comprehensive national claims database in Japan. We assessed the effectiveness and safety profile of regorafenib among
